Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis

Min-Che Tung1,2,12, Yung-Wei Lin3,4,12, Wei-Jiunn Lee3,5, Yu-Ching Wen3, Yu-Cheng Liu2, Ji-Qing Chen2,6, Michael Hsiao7, Yi-Chieh Yang2,8,9,10,11, and Ming-Hsien Chien1,2,9,10

© The Author(s) 2022

Renal cell carcinoma (RCC) is one of the most lethal genitourinary malignancies with poor prognoses, since it is largely resistant to chemotherapy, radiotherapy, and targeted therapy. The persistence of cancer stem cells (CSCs) is the major cause of treatment failure with RCC. Recent evidence showed that dopamine receptor D2 (DRD2)-targeting antipsychotic drugs such as penfluridol exert oncogenic effects on several cancer types, but the effect of penfluridol on RCC remains unknown. Here, we uncovered penfluridol suppressed in vitro cell growth and in vivo tumorigenesis of various RCC cell lines (Caki-1, 786-O, A498, and ACHN) and enhanced the Survivin (survivin)-triggered growth inhibition on clear cell (cc)RCC cell lines. Mechanistically, upregulation of endoplasmic reticulum (ER) stress-induced unfolded protein response (UPR) was critical for autophagy-mediated apoptosis induced by penfluridol. Transcriptional inhibition of OCT4 and Nanog via inhibiting GLI1 was important for penfluridol-induced stemness and proliferation inhibition. The anticancer activities of penfluridol on ccRCC partially occurred through DRD2. In clinical ccRCC specimens, positive correlations of DRD2 with GLI1, OCT4, and Nanog were observed and their expressions were correlated with worse prognoses. Summarizing, DRD2 antagonists such as penfluridol induce UPR signaling and suppress the GLI1/OCT4/Nanog axis in ccRCC cells to reduce their growth through inducing autophagy-mediated apoptosis and stemness inhibition. These drugs can be repurposed as potential agents to treat ccRCC patients.

Cell Death and Disease (2022) 13:400; https://doi.org/10.1038/s41419-022-04828-3

INTRODUCTION

Renal cell carcinoma (RCC) accounts for almost 90% of kidney tumors and is among the top 10 malignant cancers worldwide. Based on the pathological features, the most common RCC subtype is clear cell (cc)RCC, followed by papillary (p)RCC [1]. Until now, surgical management of primary tumors remains the gold standard of localized RCC treatment. However, around 25%–30% of newly diagnosed patients already have metastatic RCC, and almost 40% of patients that undergo surgical treatment experience RCC recurrence [2]. A high metastatic index of RCC conveys resistance to radiation and chemotherapies, and this led to the development of new therapeutic agents such as target-based therapies. For example, the vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitor (TKI), sunitinib (sunitinib), demonstrated efficacy in treating mRCC. Approximately 70% of patients show an initial response to VEGF TKIs, but patients eventually acquire resistance and the disease progresses as the tumor develops evasive mechanisms in response to VEGF TKI [3, 4]. Therefore, drugs targeting metastasis-initiating cells would be of great interest.

RCC is a very heterogeneous class of tumors, which comprises different populations of tumors that originate from the highly heterogeneous epithelium of renal tubules [5]. Cancer stem cells (CSCs) are small subpopulations of cancer cells harboring the self-renewal ability to drive tumor growth and cause tumor heterogeneity [6]. In addition to cancer development, CSCs are also responsible for disease recurrence, metastasis, and cancer aggressiveness, including treatment resistance such as chemotherapy, radiotherapy, and targeted therapies [4, 7, 8]. Therefore, it would be of great interest to develop new therapeutic drugs that target CSCs, based on molecular mechanisms that regulate stem cell properties.

Dopamine is a major catecholamine neurotransmitter, which binds to dopamine receptors (DRs), and it thus play an important
role in the central nervous system (CNS) including sleep, working memory, emotions, learning, and so on. Dysfunction of the dopaminergic system is related to schizophrenia and Parkinson’s disease (PD), and targeting DRs by antagonists is the principal approach [9]. In addition to their roles in the CNS, the dopamine-DR axis also has peripheral functions in regulating gastrointestinal motility, cardiovascular function, immune system, and kidney function [10–12]. DRs are G protein-coupled receptors comprising DRD1, DRD2, DRD3, DRD4, and DRD5, which are divided into D1-like receptors (DRD1 and DRD5) and D2-like receptors (DRD2, DRD3, and DRD4) according to their different regulatory actions against adenylyl cyclase (AC) activity [10]. Previous epidemiological studies declared that patients with schizophrenia or PD who receive DR antagonists have a lower cancer incidence [13–15], suggesting that DR antagonists may be suitable for repurposing for cancer treatment. Actually, increasing evidence shows that DRs, especially DRD2, is associated with the regulation of tumor behaviors in various cancer types, including proliferation, apoptosis, autophagy, and stemness [16]. For example, pimozide, a DRD2 inhibitor, was reported to induce cell-cycle G1 arrest and apoptosis in pancreatic cancer cells [17]. Another DRD2 blocker, thiioridazine, was shown to induce autophagy in ovarian cancer cells [18]. Trifluoperazine, a clinically used antipsychotic that targets DRD2, was demonstrated to suppress growth of CSCs and overcome drug resistance of lung cancer [19].

Penfluoridol, a diphenylbutylpiperidine antipsychotic drug, has a longer elimination half-life than thiioridazine, trifluoperazine, and pimozide when used to treat schizophrenia via targeting DRD2 [20, 21]. Recently, a few studies including those from our laboratory investigated the anticancer effects of penfluoridol on several cancer types, especially breast, lung, colon, pancreatic, and brain cancers [20, 22, 23]. Until now, the anticancer potential of penfluoridol against RCC is still unknown. Moreover, none of the previous studies investigated the anticancer activity of penfluoridol that is due to D2-receptor antagonism. Therefore, this study investigated the anticancer effects of penfluoridol against RCC in vitro and in a tumor xenograft model and examined possible underlying mechanisms including DRD2. We further investigated whether penfluoridol treatment could potentially suppress RCC tumor growth through the eradication of RCC CSCs.

MATERIALS AND METHODS

Materials

Penfluoridol (P3371), dopamine hydrochloride (H8502), quinpirole hydrochloride (Q102), 4-phenylbutyric acid (4-PBA), 3-methylamphetamine (3-MAN), and α-sarcosine (Cambridge, UK). GAPDH and β-actin were respectively purchased from MedChemExpress (Monmouth Junction, NJ, USA) and ChemCruz (TE, Hissen, Netherlands). Primary antibodies against cleaved caspase-3, cleaved poly(ADP ribose)polymerase (PARP), LC3, p62, and unfolded protein response (UPR) pathways including glucose-related protein 78 (GRP78), CCAAT-enhancer-binding protein homolog protein (CHOP), and phosphorylated-eIF2α were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies specific for β-actin-1, GLI1, OCT4, lamin A/C, and Nanog were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) or Abcam (Cambridge, UK). GAPDH and α-tubulin loading control antibodies were purchased from Proteintech (Rosemont, IL, USA). The OCT4 CR4 pGfireGreenFire Response Reporter construct was purchased from System Biosciences (Palo Alto, CA, USA). Fetal bovine serum (FBS), antibiotics, and all medium additives were obtained from Life Technologies (Gaithersburg, MD, USA). Unless otherwise specified, other chemicals used in this study were purchased from Sigma Chemical (St. Louis, MO, USA).

Cell lines and cell culture

The 786-O, Caki-1, A498, and ACHN RCC cell lines with different Von Hippel-Lindau (VHL) statuses were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were maintained in RPMI-1640 (for 786-O) or minimum essential medium (MEM; for Caki-1, ACHN, and A498) media supplemented with 10% FBS, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified incubator containing 5% CO2 at 37 °C. All cells were routinely tested and were negative for mycoplasma.

Cell viability assay

The cytotoxic effects of penfluoridol and sunitinib on cell viability were determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) or CCK-8 (Sigma-Aldrich) assay. Cells were seeded at a density of 104 cells/well in 96-well plates and incubated for 24 h. Then RCC cells were treated with indicated concentrations of penfluoridol for another 24 h. At the end of the incubation period, the medium was removed, and 200 µl of MTT was added or 10 µl of WST-8 was directly added without removing the medium. Viable cells reduce MTT or WST-8 to a colored formazan product, and this was detected at 570 or 490 nm absorbance using a microplate reader (MQX200; Bio-Tek Instruments, Winooski, VT, USA).

Colony-forming assay

RCC cells (101 cells/well) were seeded into six-well dishes for 24 h of incubation and further treated with penfluoridol at the indicated concentration (0.25–5 µM) for another 24 h. Cells were then continuously incubated in new fresh medium with or without penfluoridol for 7–10 days, cells were fixed with methanol and stained with 0.1% crystal violet, and colonies were manually counted using free ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Sphere-forming assay

RCC cells (5 × 103 cells/well) were seeded in ultra-low attachment six-well plates (Corning, Tewksbury, MA, USA) containing serum-free medium supplemented with 2% B-27 supplement (ThermoFisher Scientific, Rockford, IL, USA). 20 ng/ml recombinant human epidermal growth factor (EGF) and fibroblast growth factor (FGF; Corning), and penicillin/streptomycin. After 7–10 days of incubation at 37 °C in a 5% CO2 humidified atmosphere, each sphere was treated with penfluoridol when its diameter reached 100 µm. After the penfluoridol (2.5 µM) treatment for 72 h, the number of sphere colonies was measured under an inverted phase-contrast microscope.

Lentiviral production and infection

293 T packaging cells were co-transfected with 10 µg of the OCT4 CR4 pGreenFire Response Reporter construct or (sh)RNA construct of DRD2 (target sequence: GCC CTT CTT CAT CAC ACA CAT) together with 10 µg of pCMVDR8.91 (the packaging vector) and 1 μg of pMD.G (the envelope vector). The transfection medium was removed and replaced with fresh growth medium containing 5% FBS. At 48 h later, viral supernatants were collected through centrifugation at 1500 rpm for 5 min. Then, RCC cells were infected with fresh lentivirus-containing medium (supplemented with 8 µg/mL polybrene) for 24 h and subjected to the following assays.

Extraction of RNA and reverse-transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from RCC cells using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and reverse-transcribed into complementary cDNA using an 1Script™ cDNA Synthesis kit (Bio-Rad). Gene amplification was carried out using OmicsGreen 5X qPCR Master Mix with StepOnePlus™ Real-Time PCR Systems (Applied Biosystems, Carlsbad, CA, USA). GAPDH was used to normalize messenger (m)RNA levels, and primer sequences involved in the RT-qPCR are listed in Table 1.

Table 1. The primer sequences used in RT-qPCR analysis.

| Primer Name | Sequence |
|-------------|----------|
| OCT4_F | CTTGCGTGCAAAAGTTGGGTGAGGA |
| OCT4_R | CTGCGACTGTTGGGGTCG |
| Nanog_F | ATTAGCTTCCATATACAGAGAT |
| Nanog_R | TGCTGCTCAACTGTGATTCTT |
| GAPDH_F | GTCCTACGCGGTCCTACACC |
| GAPDH_R | AGGCGATGCTGATAGTCTTGGCC |
Gene expressions were normalized using ΔΔCt relative to GAPDH. Expression changes were analyzed with the 2^−ΔΔCt method [24].

**Tumorigenicity in vivo xenograft and limiting dilution assay**

Caki-1 cells were treated with vehicle or 5 μM penfluridol for 48 h and resuspended at 10^6, 10^5, or 10^4 cells in 100 μl PBS. Suspended cells were mixed with 100 μl Matrigel (BD Biosciences, San Jose, CA, USA) and subcutaneously injected into the right flank of NOD-scid IL2Rγnull (NSG) mice (4~5 weeks old). After transplantation, the tumor size was measured weekly with calipers, and the tumor volume was estimated by the following formula: tumor volume (mm^3) = 1/2 × length × width^2. At the end of the experiment, tumors were dissected out, and immunohistochemical (IHC) staining was performed. The experimental protocols used herein were evaluated and approved by the Academia Sinica Institutional Animal Care and Utilization Committee (19-11-1367).

**Supravital cell staining with acridine orange (AO) to detect autophagy**

Basic evidence of autophagy induced in cells is the gradual formation of acidic vesicular organelles (AVOs) [25]. Herein, RCC cells were stained with AO (Sigma) to detect the formation and accumulation of AVOs according to previously published procedures [26]. Briefly, cells were seeded into

---

**Fig. 1** Short-term and long-term proliferation inhibitory effects of penfluridol on renal cell carcinoma (RCC). A Four RCC cell lines including papillary type (ACHN) and clear cell type (Caki-1, A498, and 786-O), were treated with the indicated concentrations of penfluridol (1.25, 2.5, 5, 10 and 20 μM) or dimethyl sulfoxide (vehicle control) for 24 h, and an MTT assay was performed to determine cell viability. Data are presented as the mean ± standard deviation (SD) from three independent experiments. Values of the half maximal inhibitory concentration (IC_{50}) of these cells are shown in the lower panel. B and C Colony-forming abilities of 786-O and A498 cells after treating cells with the indicated concentrations of penfluridol for 7 days (B) or 24 h (C). Upper panels of B, C: representative photomicrographs. Lower panels of B, C: values are presented as the mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to those of the vehicle group. ns: not significant. D After treatment of A498, 786-O, or Caki-1 cells with 5 μM penfluridol and/or 20 μM sunitinib/sutent for 24 h, the proliferative abilities of these ccRCC cells were determined by a CCK-8 assay. **p < 0.01 and ***p < 0.001 compared to those of the vehicle group. **p < 0.01 and ***p < 0.001 compared to those of the sunitinib/sutent only group.
24-well plates and treated with 7.5 μM penfluridol for 18 h. Subsequently, AO was added to the medium at a final concentration of 1 μg/mL for 15 min, and cells were then washed with phosphate-buffered saline (PBS). In AO-stained cells, the cytoplasm and nuclei fluoresce bright green, whereas acidic compartments fluoresce bright red. Images were captured with a Zeiss Axiophot fluorescence microscope (Carl Zeiss Microimaging, Gottingen, Germany).

**Nuclear and cytosolic protein extraction and Western blot analysis**

For whole-cell protein extraction, cells were washed with cold PBS and lysed with radioimmunoprecipitation assay (RIPA) buffer as described previously [27]. For nuclear and cytosolic protein extraction, protein extracts were prepared using an NE-PER Cytoplasmic and Nuclear Protein extraction kit according to the manufacturer’s instructions (ThermoFisher Scientific).
Fig. 2 Autophagic cell death triggered by penfluirdiol via inducing the endoplasmic reticular (ER) stress-mediated unfolded protein response (UPR). A Upper panel: Acidine orange staining was used to detect acidic vesicular organelle (AVO) formation after 7.5 μM penfluirdiol treatment for 18 h in A498 and 786-O cells and analysis under a fluorescence microscope. Lower panel: The same cells were serum-starved for 48 h as a positive control of cell autophagy. B A498 and 786-O cells were treated with various concentrations of penfluirdiol for 18 and 24 h, respectively and the expression of p62 and Beclin-1, and turnover of LC3 were detected by Western blot (WB) analysis. C and D 786-O cells were pretreated with 20 μM of 3-methylamphotetamine (3-MA) for 1 h, followed by penfluirdiol treatment for 24 h. LC3 turnover and growth inhibitory effects triggered by penfluirdiol and penfluirdiol + 3-MA were respectively determined by a WB analysis (C) and colony-formation assay (D). E and F A498 and 786-O cells were treated with various concentrations of penfluirdiol for 24 h (E) or 7.5 μM penfluirdiol for the indicated time points (F), and unfolded protein response (UPR) signals, glucose-related protein 78 (GRP78), CCAAT-enhancer-binding protein homologous protein (CHOP), and phosphorylated elf2α were detected by a WB analysis. G 786-O and A498 cells were pretreated with or without 4-phenylbutyric acid (4-PBA) (1 mM) for 1 h, followed by penfluirdiol (7.5 μM) treatment for 24 h. LC3 turnover and CHOP expression in both cells were detected by a WB analysis. H A498 cells were treated with either penfluirdiol or penfluirdiol + 4-PBA, and the colony-forming abilities were further evaluated. ***p < 0.001 compared to those of the vehicle group. a p < 0.05 and **p < 0.01 compared to those of the penfluirdiol only group.

Scientific, Rockford, IL, USA). The protein concentration was determined with a Bio-Rad protein assay reagent (Bio-Rad, Hercules, CA, USA), with bovine serum albumin (BSA) as the standard. A Western blot analysis was performed with indicated primary antibodies and horseradish peroxidase-conjugated secondary antibodies according to previously described detailed processes [27].

RESULTS
Penfluirdiol attenuates the proliferative and colony-forming abilities of human RCC cells harboring different VHL statuses and enhances the antiproliferative effect of sunitinib
ccRCC represents 75% of all RCC cases, and about 80% of ccRCC cases harbor mutations of the tumour-suppressive gene, VHL [28]. Herein, we used four RCC cell lines including ccRCC (Caki-1, A498, and 786-O) and pRCC (ACHN) harboring either the wild-type (WT) or mutant VHL gene to evaluate short-term treatment (24 h) effects of penfluirdiol at the indicated concentrations (0, 1.25, 2.5, 5, 10 and 20 μM) on cell proliferation. According to results from the MTT assay, values of the half-maximal inhibitory concentration (IC_{50}) of penfluirdiol on cell viability were 8.42, 6.19, 7.24, and 6.28 μM in Caki-1, A498, 786-O, and ACHN cells, respectively (Fig. 1A). In addition, a colony formation assay was used to evaluate the long-term anticancer effect of penfluirdiol. After treating ccRCC cells (A498, and 786-O) with penfluirdiol for 7 days, the colony-forming abilities of those cells were all concentration-dependently suppressed by penfluirdiol, and penfluirdiol at 1 μM showed significant anti-colony-forming activity (Fig. 1B). Even though 24 h treatment with 2.5 μM penfluirdiol still effectively reduced the colony-forming ability of 786-O and A498 cells (Fig. 1C), we further observed the enhanced effects of penfluirdiol in combination with sunitinib/sutent, first-line therapy for RCC, on inhibition of proliferation of ccRCC cells (Fig. 1D). These results suggested that penfluirdiol would likely be useful as a therapeutic agent in managing ccRCC.

Penfluirdiol triggers autophagic cell death in ccRCC cells via inducing the ER stress-mediated UPR
To further elucidate the type of cell death caused by penfluirdiol, ccRCC cells treated with penfluirdiol were tested for autophagy. Autophagy is characterized by AVO formation, which is detected by vital staining with AO, and we observed that the number of AVOs was significantly higher in penfluirdiol-treated 786-O and A498 cells compared to the untreated group (Fig. 2A, upper panel). Serum-starvation of both ccRCC cell lines was used as a positive control for cells undergoing autophagy (Fig. 2A, lower panel). Levels of LC3-II (an autophagosome component) were positively correlated with autophagy, and we observed that penfluirdiol treatment induced concentration-dependent conversion of LC3 I to LC3 II in ccRCC cell lines. Other autophagy markers including p62 (an adaptor protein for fusion autophagosome and autolysosome degradation) and Beclin-1 (critical for phagophore membrane nucleation) were also induced by penfluirdiol in ccRCC cell lines (Fig. 2B and Supplementary Fig. 1). In addition, we observed that the autophagy inhibitors, 3-MA and 3AR405,
reversed penfluridol-induced turnover of LC3 or inhibition of colony formation and proliferation in ccRCC cells (Fig. 2C, D and Supplementary Fig. 2), suggesting that penfluridol may confer cytotoxicity partly through inducing autophagic cell death. Previous studies demonstrated that misfolded proteins accumulating in the ER can trigger the ER stress-mediated UPR and further induce autophagic cell death in cancer cells [29]. We next investigated whether penfluridol induced ER stress in ccRCC cells. UPR-related chaperone proteins and other UPR-related markers in penfluridol-treated ccRCC cells (786-O and A498) were evaluated by a Western blot analysis which showed that penfluridol treatment caused concentration (2.5, 5, and 7.5 μM)- and time-dependent (4, 8, and 24 h) induction of glucose-related protein 78 (GRP78) and...
CCAAT-enhancer-binding protein homologous protein (CHOP) expressions, and phosphorylation (p) of eIF2α (Fig. 2E and F). To further investigate the linkage between penfluridol-induced ER stress and autophagy in ccRCC cells, the ER stress inhibitors 4-phenylbutyric acid (4-PBA) was used. We found that penfluridol-induced increases in CHOP and LC3-II were all significantly reversed by both ER stress inhibitors in 786-O, A498, and Caki-1 cells (Fig. 2G and Supplementary Fig. 3). Pretreatment with 4-PBA also significantly reversed penfluridol-induced inhibition of colony formation in A498 cells (Fig. 2H). Taken together, the ER stress-mediated UPR is involved in penfluridol-induced autophagic cell death in ccRCC cells.
Penfluridol inhibits spherogenicity of clear cell renal cell carcinoma (ccRCC) cells through targeting pluripotent transcription factors. A 786-O and A498 cells were seeded on ultra-low attachment six-well plates which allowed for tumor spheroid formation. Several days after seeding, spheroids had formed (with an approximate size of 100 μm), and then they were treated with 2.5 μM of penfluridol for 72 h. Representative images of spheroids derived from both cell lines are shown in the left panels. Scare bar, 100 μm. Spheroid numbers are reported in the right panels. \( p < 0.05 \) compared to those of the vehicle group. B ccRCC cells were treated with vehicle or penfluridol at indicated concentrations for 72 h to detect mRNA levels of OCT4 using an RT-qPCR. Quantitative results of OCT4 mRNA levels were adjusted to GAPDH mRNA levels. C 786-O cells were transfected with the CR4 region of the OCT4 promoter-driven luciferase construct for 24 h and then treated with the vehicle or penfluridol at indicated concentrations. After 24 h of treatment, luciferase activities were further determined. Values from B and C are presented as the mean ± standard deviation (SD) of three independent experiments. \( p < 0.05, * p < 0.01, ** p < 0.001 \) compared to those of the vehicle group. D A498 cells were treated with 5 μM penfluridol or the vehicle for 4 h. Cells were harvested and fractionated into cytoplasmic and nuclear fractions and then subjected to a Western blot analysis to detect OCT4 levels. α-Tubulin and lamin A/C were respectively used as the cytosolic and nuclear loading controls. E Gene Expression Profiling Interactive Analysis (GEPIA) was performed to validate higher expression of OCT4 transcript in ccRCC samples compared to normal samples. The red box is the cancer tissue group (\( n = 523 \)), and gray is the normal tissue group (\( n = 100 \)). \( p < 0.05 \) compared to the normal tissue group. F Kaplan-Meier plot of overall (left panel) and disease-specific (right panel) survival of patients with ccRCC stratified by OCT4 expression levels. A log-rank test was used to show differences between the groups. G Combined analysis of the influence of OCT4 and Nanog expressions on the overall (left panel) and disease-specific (right panel) survival rates of ccRCC patients. The ccRCC dataset from F and G was retrieved from TCGA.

**Coordinated regulation of autophagy and apoptosis is involved in ER stress-mediated cytotoxic effects of penfluridol in ccRCC cells**

Autophagy and apoptosis have taken center stage as the principal mechanisms of programmed cell death in mammalian tissues [30]. Moreover, CHOP plays an important role in ER stress-induced apoptosis [31]. Therefore, we further checked if apoptosis also plays a role in the death of ccRCC cells induced by penfluridol. Caspase-3 activation-mediated PARP cleavage is a hallmark of apoptosis. Results from Western blotting showed that penfluridol concentration-dependently induced LC3-II formation and caspase-3 activation in 786-O, A498, and Caki-1 ccRCC cells, and the dominant inducing effects of LC3 turnover and caspase-3 cleavage were respectively observed at 5 and 7.5 μM of penfluridol treatment (Fig. 3A). A similar cytotoxic effect of penfluridol was observed in the ACHN pRCC cell line (Supplementary Fig. 4). Moreover, according to data from the staining of 7.5 μM penfluridol-treated ccRCC cells with Hoechst 33342, we found typical morphological changes of cellular apoptosis, such as condensed nuclear chromatin and nuclear fragmentation (Fig. 3B), suggesting that penfluridol can also induce apoptotic cell death in RCC. To further investigate the crosstalk between ER stress-mediated autophagy and apoptosis induced by penfluridol, the early autophagy inhibitor, 3-MA, and the late autophagy inhibitor, Bafilomycin A and CO, were used. Pretreatment of RCC cells with Bafilomycin A or CO respectively enhanced penfluridol-induced LC3-II production and rescued penfluridol-induced PARP cleavage, compared to that of penfluridol treatment only (Fig. 3C and Supplementary Fig. 5, Left panel). The penfluridol-induced apoptotic effect was also reversed by the early autophagy inhibitor, 3-MA (Supplementary Fig. 5, Right panel). In addition, pretreatment of 786-O and A498 cells with 4-PBA, significantly reversed the penfluridol-induced increase of PARP cleavage (Fig. 3D). These results indicated that RCC cell growth inhibition modulated by penfluridol was associated with induction of ER stress-triggered autophagy leading to apoptosis.

**Penfluridol attenuates the self-renewal potential of ccRCC cells through regulating pluripotent transcription factors**

Previous studies demonstrated that penfluridol can attenuate CSCs of glioblastoma multiforme (GBM) [32]. Sphere formation is regarded as a defining trait of CSCs, so we next investigated whether penfluridol could suppress the volume of ccRCC spheroids using a sphere-forming assay. From photomicrographs presented in Fig. 4A, we observed that both 786-O and A498 ccRCC cells could grow as spheroids in 3D culture. Compared to the vehicle-treated group, 786-O or A498 spheroids treated with 2.5 μM of penfluridol for 72 h exhibited decreased sphere diameters (left panel) and numbers (right panel). Taken together, our results suggested that penfluridol not only induced cell death of ccRCC cells, but also reduced the growth of ccRCC spheroids. Given the inhibitory effect of penfluridol on the CSC phenotype, its effect on pluripotent transcription factors such as OCT4, which endows a self-renewal property of cancer cells [33], was then evaluated in ccRCC cells. As shown in Fig. 4B, after treatment of 786-O, A498, and Caki-1 cells with penfluridol for 72 h, mRNA expression levels of OCT4 had significantly decreased. OCT4 conserved region 4 (CR4)-driven luciferase reporter activity was also suppressed by receiving penfluridol in 786-O cells in a concentration-dependent manner (Fig. 4C). In addition to the transcriptional inhibitory effect of penfluridol on the OCT4 gene, nuclear localization of the OCT4 protein was also blocked after 4 h of treatment of A498 ccRCC cells with penfluridol (Fig. 4D). In addition to OCT4, the mRNA expression and nuclear localization of Nanog, a downstream target of OCT4 [34], were also suppressed by penfluridol treatment in ccRCC cells (Supplementary Fig. 6). In clinical specimens, significantly higher OCT4 transcripts were observed in ccRCC tumors compared to normal tissues from TCGA and Genotype-Tissue Expression (GTEx) datasets (Fig. 4E). The Kaplan-Meier (KM) plot revealed a shorter overall survival (OS) and disease-specific survival (DSS) of ccRCC patients with high OCT4 or Nanog expression than patients with low OCT4 or Nanog expression (Fig. 4F and Supplementary Fig. 7). Moreover, from the same TCGA database described above, patients with OCT4high/Nanoghigh ccRCC tumors had the worst OS and DSS rates compared to those with OCT4high/Nanoglow, OCT4low/Nanoghigh, or OCT4low/Nanoglow tumors (Fig. 4G). Taken together, clinical data indicated that the upregulation of OCT4 and Nanog is a critical event in promoting the progression of ccRCC. Negative regulation of CSC properties in ccRCC by penfluridol might be through targeting OCT4 and Nanog.

**Penfluridol suppresses growth of ccRCC via targeting GLI1-mediated expressions of pluripotent transcription factors**

GLI1, an effector molecule of the Hedgehog (HH) pathway, was reported to promote CSC properties by inducing expressions of OCT4, Nanog, and Sox2 [32]. We further tested whether penfluridol can suppress the OCT4-mediated growth of ccRCC via targeting GLI1. A Western blot analysis identified decreased expression of GLI1 following penfluridol treatment in ccRCC cells (786-O, Caki-1, and A498) harboring the WT or mutant VHL gene (Fig. 5A and Supplementary Fig. 8). Next, we investigated relationships among penfluridol-mediated inhibition of GLI1, stemness, and cell growth. Treatment of ccRCC cells with the GLI1-specific inhibitor, GANT58, significantly inhibited cell proliferation (Fig. 5B) and OCT4 and Nanog mRNA expressions (Fig. 5C). Combined treatment with GANT58 and penfluridol further enhanced penfluridol-induced inhibition of cell proliferation,
OCT4 and Nanog mRNA expressions, and induction of PARP cleavage, but not LC3 turnover (Fig. 5B–D). Taken together, these results indicated that GLI1-mediated expressions of OCT4 and Nanog might play critical roles in anti-CSC efficacy of penfluridol against ccRCC growth. Clinical evidence showed that high GLI1 expression was correlated with poor OS and DSS in patients with ccRCC (Fig. 5E). We further analyzed 510 ccRCC human samples using the cBioportal platform and observed that GLI1 expression was significantly correlated with OCT4 or Nanog expression (Fig. 5F). Moreover, patients with GLI1\textsuperscript{high}/OCT4\textsuperscript{high}/Nanog\textsuperscript{high} ccRCC tumors had the shortest OS and DSS times compared to the other groups (Fig. 5G).
Fig. 5 Penfluridol inhibits growth of clear cell renal cell carcinoma (ccRCC) cells via targeting GLI1-mediated expressions of pluripotent transcription factors. A 786-O and Caki-1 cells were treated with the indicated concentrations of penfluridol for 24 h. Cell lysates were probed with antibodies against GLI1 and GAPDH. B and C 786-O or Caki-1 cells were pretreated with GANT58 (5 μM) and penfluridol treatment for 24 or 48 h. The cell proliferative ability and mRNA levels of pluripotent transcription factors (OCT4 and Nanog) were respectively measured by CCK8 (B) and RT-qPCR (C) analyses. Quantitative results of OCT4 and Nanog mRNA levels were adjusted to GAPDH mRNA levels. **p < 0.01 and ***p < 0.001 compared to the vehicle group. p < 0.05, #p < 0.01, and ##p < 0.001 compared to the penfluridol–GANT58 group. D 786-O cells were pretreated with GANT58 (5 μM) for 1 h followed by penfluridol (7.5 μM) treatment for 24 h. LC3 turnover and poly(ADP ribose) polymerase (PARP) cleavage in cells were detected by a Western blot analysis. GAPDH was used as an equal loading control. E Kaplan-Meier plot of overall (left panel) and disease-specific (right panel) survival rates of patients with ccRCC stratified by GLI1 expression levels. A log-rank test was used to show differences between groups. F Correlation Analysis of The Cancer Genome Atlas (TCGA) ccRCC databases (TCGA, PanCancer Atlas) using cBioPortal revealed the positive correlation between GLI1 expression and OCT4 or Nanog. G Combined analysis of the influence of GLI1, OCT4, and Nanog expressions on the overall (left panel) and disease-specific (right panel) survival rates of ccRCC patients. The ccRCC dataset from E and G was retrieved from TCGA.

Suppression of tumorigenesis by penfluridol in human ccRCC xenograft models

Since CSCs are defined by their higher tumor-initiating ability, we subsequently determined if the anti-CSC activity of penfluridol occurs in vivo using xenotransplantation limiting dilution assays (LDAs). Vehicle- and penfluridol-pretreated Caki-1 cells were subcutaneously injected into NSG mice with serially diluted cell numbers. Two weeks after cells were injected, vehicle-treated Caki-1 cells initiated tumor formation in six of six mice, five of five mice, and none of five mice injected with 10<sup>6</sup>, 10<sup>5</sup>, and 10<sup>4</sup> cells, respectively. In contrast to vehicle-treated Caki-1 cells, penfluridol-pretreated cells initiated tumor formation in three of six mice, two of five mice, and none of five mice injected with 10<sup>6</sup>, 10<sup>5</sup>, and 10<sup>4</sup> cells, respectively. After 5 weeks after injection of 10<sup>6</sup> cells, tumor formation was observed in four of five mice and one of five mice in vehicle- and penfluridol-treated cells, respectively (Fig. 6A). Although xenografts injected with 10<sup>6</sup> or 10<sup>5</sup> cells all produced tumors by the 5th week, tumor sizes in the penfluridol-pretreated groups were markedly reduced compared to those of the vehicle-pretreated groups (Fig. 6B). Similar results were observed in tumor volumes recorded at the 3rd, 4th, and 5th weeks after tumor cell inoculation (Fig. 6C), indicating that tumors derived from penfluridol-pretreated Caki-1 cells grew more slowly than did tumors derived from vehicle-treated Caki-1 cells. After terminating the experiment, tumors were removed and analyzed by IHC. In agreement with our in vitro findings, we observed downregulation of GLI1 and proliferation index Ki-67 in penfluridol-pretreated tumors compared to vehicle-treated tumors. These results indicated that penfluridol suppresses tumorigenesis of ccRCC by suppressing GLI1-driven tumor growth.

Penfluridol induces ER stress-mediated cell death and stemness inhibition through targeting DRD2 in ccRCC cells

The mechanism of penfluridol against schizophrenia is thought to be blockade of DRs, especially DRD2 [20]. Actually, significantly higher DRD2 transcripts were observed in ccRCC compared to normal tissues from the GSE15641 dataset of the GEO database (Fig. 7A). We also observed that knockdown of DRD2 in RCC significantly reduced the cell proliferation and colony-forming abilities (Supplementary Fig. 9A and B). Until now, there has been no evidence that the anticancer activity of penfluridol is due to DRD2 antagonism. Herein, we used dopamine to compete with penfluridol for binding to DRD2 and found that combination treatment of ccRCC cells with dopamine and penfluridol respectively reversed penfluridol-induced upregulation of CHOP, cleaved PARP, and LC3-II and inhibition of OCT4 mRNA expression in ccRCC cells harboring the WT or mutant VHL (Fig. 7B and C). Functionally, dopamine respectively reversed penfluridol-induced inhibition of cell proliferation (Fig. 7D) and colony formation (Fig. 7E) in various ccRCC cell lines. Because dopamine is not a DRD2-specific agonist, we further used the selective DRD2 agonist, quinpirole, to confirm our results and observed that penfluridol-induced inhibition of cell proliferation was also significantly reversed by quinpirole in 786-O cells (Supplementary Fig. 10). In contrast, depletion of DRD2 further enhanced penfluridol-triggered ER stress, autophagy, and cytotoxicity (Supplementary Fig. 9C and D). These results suggested that DRD2 is involved in the penfluridol-induced increase in ER stress, inhibition of stemness, and autophagy-mediated apoptosis in ccRCC cells. In patients with ccRCC from TCGA database, we observed that DRD2 expression was positively correlated with GLI1, OCT4, and Nanog expressions (Fig. 7F) and poor prognoses of patients (Fig. 7G). Taken together, DRD2 might be a critical target involved in the anticancer activities of penfluridol in ccRCC cells.

DISCUSSION

Interesting epidemiologic studies indicated reduced cancer risk was observed in patients with various neurological diseases such as schizophrenia and PD, for which dopaminergic drugs were used. Recently, DRD2 was reported to be upregulated in various cancers and tied to the stemness of solid and nonsolid tumors [35]. Therefore, DRD2 antagonists might be promising repurposed drugs for cancer treatment. Actually, DRD2 antagonists were reported to have anticancer efficacy in cell culture and animal models in several cancer types [20, 22, 23, 35]. Nevertheless, the anticancer effects of DRD2 antagonists and the precise mechanisms of DRD2 signaling and their relationships to RCC progression remain poorly understood.

Herein, we used the DRD2 antagonist, penfluridol, to identify the critical role of DRD2 in treating RCC, especially ccRCC, and explored the relevant mechanisms for its possible therapeutic application. First, we demonstrated that penfluridol significantly inhibited cell proliferation and colony formation in concentration-dependent manners in vitro and attenuated the tumorigenic ability in vivo. A mechanistic investigation revealed that penfluridol treatment induced the ER stress-mediated UPR signaling pathway, GRP78/PERK/elf2α/CHOP axis, which led to the autophagy-mediated apoptotic cell death of ccRCC cells. These results are similar to previous studies which showed that penfluridol-induced ER stress led to autophagy and ultimately induced cell apoptosis in pancreatic cancer [36, 37]. However, in this study, we observed that blocking of autophagy by several autophagy inhibitors just partly reversed penfluridol-induced inhibition of cell growth, but almost reversed the penfluridol-induced PARP cleavage. In contrast, blocking of ER stress can dramatically rescue penfluridol-induced inhibition of cell growth, suggesting autophagy-mediated apoptotic cell death might be one of the causes to explain the cytotoxic effect of penfluridol in ccRCC cells. We speculate that other forms of cell death such as necrosis or ferroptosis might be triggered by penfluridol-induced ER stress and these issues should be further investigated in our future work.

Moreover, we used the DRD2 agonists, dopamine and quinpirole, to compete with penfluridol for DRD2 binding and observed that co-treatment with a DRD2 agonist and penfluridol...
Fig. 6  Tumorigenicity in vivo xenograft and limiting dilution assay. A Upper panel, timeline of the in vivo study design for investigating the antitumor activity of penfluridol. Caki-1 clear cell renal cell carcinoma (ccRCC) cells that had been treated with penfluridol (5 µM) or the vehicle. For the limiting dilution analyses, the indicated numbers of cells were subcutaneously injected into male NOD-scid IL2Rγnull (NSG) mice (n = 5 or 6 per group). Two weeks after tumor cell injection, the tumor volume in mice was checked every week. Lower panel, numbers of tumors generated and results of the limiting dilution assay. Numbers of tumors generated by the cell lines were recorded every week and are shown in the table. B All mice were sacrificed at 5 weeks after tumor cell injection, and tumors were dissected and photographed. C Tumor development from vehicle- and penfluridol-treated groups. Tumor volumes were recorded at the 3rd, 4th, and 5th weeks after tumor cell injection and are reported as the mean ± standard error of the mean (SEM). *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the vehicle group. NS, not significant. D Caki-1 xenografts treated with vehicle or penfluridol were isolated to detect expressions of Ki-67 and GLI1 by IHC staining. Original magnification, 400x. Scale bar, 30 µm.
significantly reversed penfluridol-induced upregulation of ER stress and inhibition of cell growth, suggesting that DRD2 is a critical target of penfluridol’s anticancer activities in ccRCC. In pancreatic cancer, DRD2 inhibition by pimozide resulted in anticancer activity by inducing cell death through activating the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway leading to higher calcium levels and elevated ER stress, thus inducing apoptosis [17]. In addition to pancreatic cancer, He et al. showed that EGF receptor (EGFR) overexpression was associated with poor in vitro and in vivo responses to DRD2 antagonists [38], suggesting the mechanisms by which DRD2 signaling contributes to cancer progression appeared to
be cell-type dependent. Indeed, we also observed that DRD2 expression was positively and negatively correlated with PRKACA (PKA catalytic subunit) and EGFR expression in patients with ccRCC from TCGA database (Supplementary Fig. 11). The roles of cAMP/PKA and EGFR in the anticancer effects of penfluridol for ccRCC need to be further investigated in the future.

Recently, DRD2 was found in CSCs. For example, treatment with the DRD2 antagonist, thioridazine, revealed in vivo anti-CSC activity by reducing leukemic stem cell function in forming leukemia [39]. In our present study, results from sphere-formation and xenotransplantation limiting dilution assays also showed that penfluridol exhibits in vitro and in vivo anti-CSC activities in ccRCC. Gassenmaier et al. indicated that CXC chemokine receptor 4 (CXCR4)+ RCC cells presented CSC characteristics, such as increased resistance to TKIs, higher sphere-forming ability, and tumor growth-inducing potential in vivo, and expressed high...
levels of the stem cell-associated markers, OCT3/4, Nanog, and Sox2 [40]. Herein, we found that penfluridol transcriptionally inhibited OCT4 and Nanog expressions and enhanced the response to a TKI, sunitinib, in various ccRCC cells, but the role of CXCR4 in the anti-CSC activity of penfluridol needs to be further investigated.

GLI1 is one of three GLI transcription factors within the Hh pathway and was reported to modulate the CSC self-renewal ability through transcriptionally inducing upregulation of OCT4, Nanog, and Sox2 [32]. In addition to being a terminal effector, GLI1 also acts as a GLI target gene that elicits signal amplification [41]. Previous studies [42] and our present results indicated that GLI1 is upregulated in ccRCC compared to normal tissues and was correlated with the poor prognosis of patients with ccRCC. In addition, GLI1 overexpression by normal kidney tubular cells showed enhanced tumorigenic abilities with tumor-formation rates in an animal model [42], and the GLI1 expression level was significantly correlated with OCT4 and Nanog levels in ccRCC specimens, suggesting that GLI1 plays a critical role in the initiation and progression of ccRCC via upregulating OCT4 and Nanog. In vitro, we observed that penfluridol treatment suppressed GLI1 expression in ccRCC cells harboring WT or mutant VHL. The GLI1-specific inhibitor, GANT58, can further enhance the penfluridol-induced inhibition of proliferation, OCT4 and Nanog mRNA expressions, and induction of apoptosis. Regardless of the VHL status, GLI1 was suggested to be an important target for the growth-suppressive effect of penfluridol in ccRCC cells. Actually, Zhou et al. also indicated that GLI1 expression was not affected by the VHL status in ccRCC [42]. Recently, Ranjan et al. demonstrated that penfluridol suppresses tumor growth of GBM by inhibiting Akt-mediated GLI1 expression [32]. In ccRCC, Zhou et al. showed that the phosphatidylinositol 3-kinase (PI3K)/Akt pathway could potentiate the expression and activation of GLI1 in ccRCC cells [42], suggesting that penfluridol may suppress GLI1 expression through inhibiting the PI3K/Akt pathway in ccRCC.

The present data demonstrated the novel anticancer mechanism of the DRD2 antagonist, penfluridol, in human ccRCC which harbors the WT or mutant VHL. Penfluridol can trigger the ER stress-elicited GRP78/PERK/eIF2α/CHOP signaling pathway of the UPR, and suppress the Akt/GLI1/OCT4/Nanog axis which respectively led to autophagy and stemness inhibition and further induced apoptosis of ccRCC cells; the mechanism is schematically illustrated in Fig. 8. Our present findings strongly support repurposing penfluridol as a drug for targeting DRD2 to treat ccRCC.

DATA AVAILABILITY

All the data in the current study are available from the corresponding authors upon reasonable request.

REFERENCES

1. Chowdhury N, Drake CG. Kidney Cancer: An Overview of Current Therapeutic Approaches. Urologic Clin North Am. 2020;47:419–31.
2. Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. The New England J Med. 2017;376:354–66.
3. Butz H, Ding Q, Nofech-Mozes R, Lichner Z, Ni H, Yousef GM. Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis. Oncotarget. 2018;9:4661–74.
4. Buczek M, Escudier B, Bartnik E, Szczylak C, Czarnecka A. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient’s bed to molecular mechanisms. Biochimica et biophysica acta. 2014;1845:31–41.
5. Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol. 2013;23:3–9.
6. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25:20.
7. Bielecka ZF, Czarnecka AM, Solarek W, Kornakiewicz A, Szczylak C. Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Curr Signal Transduct Ther. 2014;8:218–28.
8. Peired AJ, Sisti A, Romagnani P. Renal Cancer Stem Cells: Characterization and Targeted Therapies. Stem Cells Int. 2016;2016:8342652.
9. Howes OD, Kambeitz J, Kim E, Stahl D, Silfstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86.
10. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000;24:125–32.
11. Armando I, Villar VA, Jose PA. Dopamine and renal function and blood pressure regulation. Compr Physiol. 2011;1:1075–117.
12. Arreola R, Alvarez-Herrera S, Perez-Sanchez G, Becerril-Villanueva E, Cruz-Fuentes C, Flores-Gutierrez ED, et al. Immunomodulatory Effects Mediated by Dopamine. J Immunol Res. 2016;2016:3160486.
13. Zhou FH, Tsai KY, Su CY, Lee CC. The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res. 2011;129:97–103.
14. Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int J Cancer. 2012;131:1904–11.
15. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry. 2010;81:215–21.
16. Wang X, Wang ZB, Luo C, Mao XY, Li X, Yin JY, et al. The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor. J Cancer. 2019;10:1622–32.
17. Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, et al. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Correlates with Slow Tumor Growth. J Gastrooncology. 2016;15:1218–31.
18.  Young M, Yu T, Tian S, Liu S, Xu J, Hu J, et al. DRD2 blocker thioridazine: A promising drug for ovarian cancer therapy. Oncol Lett. 2017;14:8171–7.
19. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respiratory Crit Care Med. 2012;186:1180–8.
20. Tuan NM, Lee CH. Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent. Molecules. 2019;24:3659.
21. Shaw V, Srivastava S, Srivastava SK. Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy. Seminars in cancer biology. Semin Cancer Biol. 2019;68:73–83.
22. Hung WY, Chang YH, Chen YC, Cheng GZ, Huang HC, Hsiao M, et al. Autophagy-governed accumulation-mediated ATP energy deprivation induced by penfluridol triggers nonapoptotic cell death of lung cancer via activating unfolded protein response. Cell Death Dis. 2019;10:538.
23. Wu SY, Wen YC, Ku CC, Yang YC, Chow JM, Yang SF, et al. Penfluridol triggers cytoprotective autophagy and cellular apoptosis through ROS induction and activation of the PP2A-modulated MAPK pathway in acute myeloid leukemia with different FLT3 statuses. J Biomed Sci. 2019:29:663.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.
25. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439–44.
26. Traganos F, Darynkiewicz Z. Lysosomal proton pump activity: supravital cell cation [41].
27. Cell Death and Disease          (2022) 13:400
ACKNOWLEDGEMENTS
This study was supported by the Taipei Medical University Research Center of Cancer Translational Medicine from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan (to M.-H. Chien). This work was also supported by grant from the Ministry of Science and Technology, Taiwan (109-2320-B-038-052-MY3 to M.-H. Chien), and the grant (110TMU-WFH-02) from Wan Fang Hospital, Taipei Medical University (to Y.-W. Lin and M.-H. Chien).

AUTHOR CONTRIBUTIONS
MHC, MCT, YCY, and YWL designed and conceived the study. WJL, YCL, JQC, YCY, and MHC performed the in vitro experiments and acquired the data. MHC and YCY performed the in silico analysis. MCT, YCY, and YCW performed the in vivo studies and analyzed data from the animal model. YWL and MH performed and analyzed the immunohistochemical experiments. MCT, YCY, and MHC wrote the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
All animal experiments were carried out in accordance with guidelines of a protocol approved by the Institutional Animal Care and Use Committee of Academia Sinica (ASIACUC).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04828-3.

Correspondence and requests for materials should be addressed to Yi-Chieh Yang or Ming-Hsien Chien.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022